News of the regulatory nod comes just weeks after the last one for Quantum. It announced CE mark expansion for Epione to treat lung tumors earlier this month.
Montpellier, France-based Quantum’s flagship Epione robot enables the early and minimally invasive treatment of abdominal tumors. It allows surgeons to treat inoperable tumors that are particularly hard to reach due to size or location. The simple, effective platform provides treatment at an early stage.
A robotic-assisted percutaneous ablation system, Epione uses a robotic arm, a navigation system and a camera. It inserts a needle through the skin to the tumor and destroys it.
Epione can treat tumors in the liver, kidney and pancreas, in addition to the lung expansion it just received. It’s treated more than 200 patients in France and the U.S. already. Expanding to the Chinese market means a potential treatment for nearly 610,000 new abdominal cancer cases each year, the company says.
“Thanks to the NMPA market authorization, we are very excited to be able to offer our Epione solution to interventional oncologists in China. This is an important step that will provide Chinese patients with an innovative and minimally invasive treatment to treat their abdominal tumors at an early stage while improving their comfort,” said Bertin Nahum, president and co-founder of Quantum Surgical.
